APA (7th ed.) Citation

Girda, E., De Meritens, A. B., Leiser, A., Stephenson, R., Nelson, D., & Rodriguez-Rodriguez, L. (2019). An open-label phase 1 trial of the safety and efficacy of daily subcutaneous spl-108 injections in combination with paclitaxel in patients with platinum-resistant, CD44+, advanced ovarian epithelial cancer. Gynecologic Oncology, 154, 93. https://doi.org/10.1016/j.ygyno.2019.04.218

Chicago Style (17th ed.) Citation

Girda, E., A. Buckley De Meritens, A. Leiser, R.D Stephenson, D. Nelson, and L. Rodriguez-Rodriguez. "An Open-label Phase 1 Trial of the Safety and Efficacy of Daily Subcutaneous Spl-108 Injections in Combination with Paclitaxel in Patients with Platinum-resistant, CD44+, Advanced Ovarian Epithelial Cancer." Gynecologic Oncology 154 (2019): 93. https://doi.org/10.1016/j.ygyno.2019.04.218.

MLA (9th ed.) Citation

Girda, E., et al. "An Open-label Phase 1 Trial of the Safety and Efficacy of Daily Subcutaneous Spl-108 Injections in Combination with Paclitaxel in Patients with Platinum-resistant, CD44+, Advanced Ovarian Epithelial Cancer." Gynecologic Oncology, vol. 154, 2019, p. 93, https://doi.org/10.1016/j.ygyno.2019.04.218.